Rosetta Genomics Sells 560,000 Additional Shares in IPO Over-Allotment | GenomeWeb
NEW YORK (GenomeWeb News) — Underwriters taking part in Rosetta Genomics’ initial public offering last month bought 562,000 additional shares as part of an over-allotment.
.
The over-allotment makes the total IPO’s net value $26.2 million on 4.3 million shares sold, after the initial sale of 3.75 million shares at $7 a share.
 
Rosetta’s stock was down 2.4 percent at $8.15 in early-afternoon trading today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.